X4 Pharmaceuticals

Clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.

Launch date

2014

Employees

Market cap

Enterprise valuation

€26m (Public information from Sep 2024)

Cambridge Massachusetts (HQ)

http://x4pharma.com

https://twitter.com/x4pharma https://www.linkedin.com/company/x4-pharmaceuticals

View job openings

Revenues, earnings & profits over time

USD	2020	2021	2022	2023	2024	2025	2026
Revenues	3.0m	-	-	-	6.3m	44.1m	102m
% growth	-	-	-	-	-	597 %	130 %
EBITDA	(59.9m)	(65.6m)	(88.6m)	(102m)	-	-	-
% EBITDA margin	(1996 %)	-	-	-	-	-	-
Profit	(62.1m)	(88.7m)	(93.9m)	(101m)	(42.6m)	(111m)	(76.5m)
% profit margin	(2071 %)	-	-	-	(675 %)	(253 %)	(75 %)
EV / revenue	34.9x	-	-	-	18.7x	2.7x	1.2x
EV / EBITDA	-1.8x	-1.0x	-1.4x	-1.4x	-	-	-
R&D budget	41.9m	50.6m	61.1m	72.0m	-	-	-
R&D % of revenue	1398 %	-	-	-	-	-	-

Date	Investors	Amount	Round
-	NeoMed Emerging Technology Partners Biomedical OrbiMed Puget Sound Venture Club Bain Capital Life Sciences Lumira Ventures	N/A	-
Apr 2015*	N/A	$15.0m	Early VC
Dec 2015	Cormorant Asset Management	$37.5m	Series A
Apr 2016*	N/A	$7.5m Valuation: $188m	Early VC
Apr 2016*	N/A	$7.5m	Debt
Nov 2016	Cormorant Asset Management	N/A	Series A
Nov 2017	Cormorant Asset Management	$27.0m	Series B
Nov 2017	N/A	N/A	IPO
Apr 2019*	N/A	$85.8m	Post IPO Equity
Nov 2019*	N/A	$65.0m	Post IPO Equity
Dec 2022*	N/A	$65.0m	Post IPO Equity
Aug 2023*	Hercules Capital	$115m	Post IPO Debt
May 2024*	Hercules Capital	$20.0m	Post IPO Debt
Total Funding		€79.1m

Tech stackLearn more about the technologies and tools that this company uses.